Magazine Article | July 5, 2018

Building New Business Models To Support Cell And Gene Therapy R&D

Source: Life Science Leader

By Lev Gerlovin and Walter Colasante

The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. There are now clinical stage development programs in gene therapy targeting almost 50 different diseases, up from 10 only a few years ago. Development programs are underway around the world, with the largest share led by U.S. and EU companies (53 percent and 32 percent, respectively) and the remainder from companies in China and South Korea.